Delcath Systems, Inc. filings document an interventional oncology company with Nasdaq-listed common stock and a liver-directed drug-device platform. Form 8-K reports furnish quarterly and annual financial results, preliminary results, Regulation FD presentations, product revenue for HEPZATO KIT and CHEMOSAT, clinical publication updates for CHOPIN, and board-authorized share repurchase activity.
The company’s proxy materials cover annual meeting governance, executive compensation, equity awards, and related shareholder voting disclosures. Delcath filings also identify its common stock, par value, trading symbol DCTH, and Nasdaq Capital Market listing, while formal exhibits provide press releases and corporate presentations used for operating, clinical, and capital-structure disclosures.
DELCATH SYSTEMS, INC. (DCTH) is the issuer whose common stock is covered by joint beneficial-ownership reports from Rosalind Advisors, Inc., Rosalind Master Fund L.P. and Rosalind Opportunities Fund I L.P., as well as Steven Salamon, President and portfolio manager of Rosalind Advisors, and Gil Aharon, Secretary and portfolio manager of Rosalind Advisors. Rosalind Advisors’ cover page reports 6,692,491 common shares issuable upon full conversion and exercise of reported securities; that count does not apply the blockers, and the reported actual beneficial ownership after those limits is lower. Its reported ownership percentage is 9.9% after giving effect to the blockers.
Preferred stock conversion is restricted if it would result in ownership above 9.99%; warrant exercise is restricted above 4.99%. The issuer had 34,698,795 common shares outstanding as of July 31, 2026.
Delcath Systems, Inc. (DCTH) reported indirect transactions by Rosalind Opportunities Fund I L.P. on October 13, 2026. The fund converted 36.27 Series E preferred shares into 3,627 common shares at a listed $10.00 conversion price; its Series E preferred position afterward was 9,112.38 shares. It also distributed 27,502 common shares in kind to limited partners for redemption requests, for no consideration. Reporting persons include Rosalind Advisors, Inc., and directors Steven A. J. Salamon and Gil Aharon; each disclaims beneficial ownership except to the extent of its or his respective pecuniary interest.
Delcath Systems, Inc. updated its corporate governance documents by amending and restating its Bylaws, effective August 12, 2026. The Board of Directors, following a recommendation from the Nominating and Corporate Governance Committee, adopted provisions specifying where certain legal disputes must be brought.
The revised Bylaws provide that, unless Delcath consents in writing to an alternative forum, the Court of Chancery of the State of Delaware (or, if it lacks subject matter jurisdiction, the federal district court for the District of Delaware) is the exclusive forum for internal corporate claims. They also state that the federal district courts of the United States are the exclusive forum for claims arising under the Securities Act of 1933. The full Bylaws are filed as Exhibit 3.1.
Delcath Systems, Inc. reported continued profitability for the quarter ended June 30, 2026, driven by growing adoption of its liver cancer therapies. Quarterly revenue was $29,133 (in thousands), up from $24,156 (in thousands) a year earlier, with HEPZATO KIT contributing $27,161 (in thousands) and CHEMOSAT $1,972 (in thousands). Gross profit reached $26,148 (in thousands), and net income was $2,668 (in thousands), or $0.07 per diluted share.
Research and development expenses rose to $10,380 (in thousands) in the quarter and $20,204 (in thousands) year-to-date as the company advances Phase 2 trials in liver‑dominant metastatic colorectal and breast cancer. Selling, general and administrative expenses also increased with U.S. commercial expansion. Delcath ended June 30, 2026 with $47,521 (in thousands) in cash and cash equivalents and $48,381 (in thousands) in short‑term investments and states that these resources, plus operating cash flows, are expected to fund operations for at least 12 months. The company has repurchased 945,665 shares for about $9.0 million under a $25.0 million authorization, leaving roughly $16.0 million available.
Delcath Systems, Inc. reported second quarter 2026 results, with total revenue of $29.1 million, up from $24.2 million a year earlier, driven by HEPZATO KIT revenue of $27.1 million and CHEMOSAT revenue of $2.0 million. Gross margin rose to 90% from 86%, while net income was $2.7 million in both periods.
Non-GAAP adjusted EBITDA was $7.6 million, compared with $9.8 million in the prior-year quarter, and operating cash flow was $5.7 million. Cash and investments totaled $95.9 million as of June 30, 2026, with no debt, supporting expansion to 31 active treatment centers and ongoing clinical trials.
For full-year 2026, Delcath increased its revenue guidance for HEPZATO KIT and CHEMOSAT to $104–$108 million, targeting gross margins of 86–89% and positive adjusted EBITDA, and highlighted approximately 30% growth in HEPZATO volume and new data and trials across uveal melanoma and metastatic breast cancer.
BlackRock, Inc. has filed as a significant holder of Delcath Systems common stock. The firm reports beneficial ownership of 1,836,121 shares of common stock, representing 5.3% of the outstanding class.
BlackRock reports sole voting power over 1,807,103 shares and sole dispositive power over 1,836,121 shares, with no shared voting or dispositive power. The filing notes that various underlying clients and funds have rights to dividends or sale proceeds, but no single such person has an interest exceeding five percent of Delcath’s total outstanding common shares.
DELCATH SYSTEMS, INC. director John Richard Sylvester received a grant of stock options for 22,500 shares of common stock at an exercise price of $11.61 per share. The options vest in equal monthly installments, with one-twelfth vesting each month starting on May 13, 2026, as long as he remains a director. Any vested options expire the earlier of 10 years from the grant date or two years after his last day of service.
DELCATH SYSTEMS, INC. director Bridget A. Martell received a grant of stock options as equity compensation. The award covers 22,500 options for common stock at an exercise price of $11.61 per share, and she now holds 22,500 options following this grant.
These options vest in equal monthly installments of one-twelfth, starting on May 13, 2026, as long as she continues serving as a director under the company’s 2020 Omnibus Equity Incentive Plan. The options expire on the earlier of 10 years from grant or two years after her service ends for vested portions.
DELCATH SYSTEMS, INC. director Elizabeth Czerepak received a grant of stock options covering 22,500 shares of common stock. The options have an exercise price of $11.61 per share and are compensation rather than an open-market purchase.
The award vests at a rate of one-twelfth per month, with the first vesting on May 13, 2026 and monthly thereafter while she remains a director under the company’s 2020 Omnibus Equity Incentive Plan. Any unexercised options will expire the earlier of 10 years from the grant date or two years after her service ends.
DELCATH SYSTEMS, INC. director Steven A. J. Salamon received a grant of stock options covering 22,500 shares of common stock. The options have an exercise price of $11.61 per share and represent a compensation-related award, not an open-market purchase.
The options vest in equal monthly installments of one-twelfth of the grant, starting on May 13, 2026, as long as he continues serving as a director under the company’s 2020 Omnibus Equity Incentive Plan. The options expire 10 years from the grant date or, for vested portions, two years after his last day of service.